Vistagen Announces Top-Line Results From Phase 3 PALISADE-2 Trial Of Fasedienol Nasal Spray In Social Anxiety Disorder
Portfolio Pulse from Happy Mohamed
Vistagen (NASDAQ:VTGN) has announced positive top-line results from its Phase 3 PALISADE-2 trial of fasedienol nasal spray for social anxiety disorder. The trial met its primary and secondary endpoints, demonstrating a statistically significant reduction in patient-reported distress and proportion of responders compared to placebo. Fasedienol was well-tolerated and demonstrated a favorable safety profile. The results highlight the potential for fasedienol to transform treatment for over 25 million people living with social anxiety in the U.S.
August 07, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vistagen's positive Phase 3 trial results for fasedienol nasal spray could potentially boost investor confidence and the company's stock price.
Positive clinical trial results often lead to increased investor confidence, which can drive up a company's stock price. Given that this is a Phase 3 trial and the drug has the potential to serve a large market (over 25 million Americans with social anxiety disorder), the impact on Vistagen's stock could be significant.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100